To study the role, safety and efficacy of ferric carboxymaltose in antenatal women.
Methodology: This will be a prospective interventional study conducted in Obstetrics and Gynaecology department of AMC MET medical college. Study group of 40 antenatal women between 20 weeks to 32 weeks of gestation will be followed through. Haemoglobin level before infusion of FCM and after 2 weeks of infusion will be estimated. The efficacy of ferric carboxymaltose will be analysed in study group. The evaluation of safety and tolerance to mother will also be monitored.
Inclusion criteria: Gestational age > 20 weeks and < 32 weeks, Haemoglobin concentration of > 6 gm% and < 8 gm%.
Exclusion criteria: Hypersensitivity reaction to any iron preparation, History of blood transfusion, History of iron overload diseases, Concomitant medical or surgical diseases.
Results: A total of 40 antenatal patients were included in our study. It’s observed that the incidence of anaemia was higher among the reproductive age group especially in pregnant women of 21 to 30 years of age, than so in age group less than 20 and more than 30. Out of which 35% were primigravida and 65% were multigravida. Among 40 patients who received Inj. Ferric carboxylate maltose, 3 patients developed drug reactions. The mean rise in haemoglobin was found to be 0.9gm/dl at the end of 15 days from treatment. Correspondingly the MCV and RDW values were up by 11fL and 4.3% respectively.
Conclusion: Ferric carboxymaltose is a safe and effective treatment option for iron deficiency anaemia in antenatal patients.